Pfizer Inc PFE

$27.82 -0.18 (-0.64%)

Valuation

Market cap
159,590,864,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.02
Forward PE
9.24
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
44,433,400
Avg volume
35,740,172
Day's range
$27.48 – $28.00
Shares out
5,699,674,000
Stochastic %K
38%
Beta
0.32
Analysts
Sell
Price target
$29.06

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

theoptionsplug Oct 9, 2:56 PM
$PFE looks BEAUTIFUL off the 50DMA! Previous resistance has become a support area with targets towards $28.55!
0 replies
ProTraderColin Oct 9, 2:49 PM
$PFE selling off now like the turd it is. Bummer.
1 replies
Sdwg Oct 9, 2:46 PM
$PFE 28 glass ceiling
0 replies
jrh34 Oct 9, 2:39 PM
$CRDF damn $PFE flopped with the $TRIL aquisition. Song and a dance they can have $CRDF and sail though a P3 for under $1 Billion. I like the odds better than $PYXS or $AUPH both of which had acquisition interest at one point.
0 replies
Diehard777 Oct 9, 2:27 PM
$PFE boom
0 replies
skiddy5 Oct 9, 2:08 PM
$T getting close to 5% divvy yield. But no growth , high debt. Why not get over 5% in a money market or $TLT or if you are a degenerate and need to chase growth ...better chances at $PFE. No idea what bull case is here. Even a fixed income play is underperforming safer opportunities.
0 replies
jackofalltrade Oct 9, 2:06 PM
$PFE BofA Securities adjust Pfizer price target from $27 to $29.
1 replies
Diehard777 Oct 9, 2:01 PM
$MRNA $PFE Investors are making major shifts, moving out of tech, finance, telecom, and consumer goods and into healthcare and defense at this point in time. (5 People are worried about global instability, trade wars, potential future viral /disease outbreaks, inflation, and recession
0 replies